市場調查報告書
商品編碼
1439264
心臟輔助設備 - 全球市場考量、競爭格局、市場預測 (2030)Cardiac Assist Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
全球心臟輔助設備市場規模將於2023年達到28.9億美元,到2030年將達到62.3億美元,預計2024-2030年期間複合年增長率為13.70%。 冠狀動脈疾病患病率上升、新療法的增長、醫療器械的可負擔性、新興國家心臟輔助器械的普及和接受度不斷提高以及醫療器械的創新和進步推動了對心臟輔助器械的需求。這是一個促成因素。
心臟輔助設備的市場動態
心臟移植被廣泛認為是世界各地末期心臟衰竭患者的第一治療選擇。 由於缺乏可供移植的器官,接受移植的患者比例有限。 最新統計數據顯示,等待心臟移植的患者人數在短短五年內增加了一倍以上。 然而,捐贈者短缺、等待時間長以及越來越多的不穩定患者正在推動心臟輔助設備的發展。
心臟輔助裝置 (CAD) 是一種機械泵,可與心臟配合使用,以提高其有效性並維持全身最佳的血流。 心臟輔助裝置用於治療末期心臟衰竭,取決於個人的需求。 由於心臟捐贈者短缺,臨時心臟輔助裝置被用來為個人提供長期援助。
根據美國心臟協會報告(2020),隨著人口老化,心臟衰竭的盛行率持續增加。 老年患者數量的增加預計將改變醫療保健服務並增加對心臟輔助設備的需求。 根據最近的一項研究《2020年全球人口老化報告》(聯合國,2020),人口老化正以驚人的速度成長。 2020年,全球65歲以上人口約為7.27億人。 到 2050 年,此類患者的數量預計將增加一倍,達到 15 億。 老年人更容易患心血管疾病,這增加了對心臟輔助設備的需求,並刺激了心臟輔助設備市場。
此外,公司正在增加基本醫療器材產品的產量。 例如,2022 年 8 月,FDA 授予 Abiomed 的 Impella ECP 可擴展經皮心臟幫浦突破性醫療器材稱號。 這項指定意味著 FDA 將優先考慮 Impella ECP 的監管審查流程,包括設計迭代、臨床試驗方案和上市前批准 (PMA) 備案。
因此,此類措施預計將有助於市場和患者治療,並推動心臟輔助設備市場的成長。
然而,植入式裝置的高治療成本和安全限制可能會對心臟輔助設備市場的成長產生一定的限制。
心臟輔助設備市場區隔分析
在心臟輔助設備市場的產品領域,心室輔助設備預計在預測期內將佔據重要份額。 這主要是由於與 LVAD 相關的技術進步、益處和應用、器官捐贈者的缺乏以及全球心臟衰竭盛行率的增加。
LVAD 旨在透過恢復正常血流來治療嚴重心臟衰竭患者。 在心臟衰竭患者體內植入 LVAD 可以挽救生命,並為器官移植贏得時間。
LVAD 高度可靠,並具有內建安全系統。
植入 LVAD 後,患者的健康狀況有所改善,並且能夠恢復/恢復運動和其他日常活動。
LVAD為嚴重心臟衰竭患者提供了中長期治療方案。 此外,政府機構的援助和有利的報銷方案預計將提振一些國家心臟輔助設備市場的前景。
因此,上述所有因素預計將推動該細分市場的成長。
本報告提供了全球心臟輔助設備市場的研究和分析,包括市場規模和預測、驅動因素和挑戰以及公司和產品概況。
Cardiac Assist Devices Market By Product (Ventricular Assist Devices [Left Ventricular Assist Devices (LVAD), Biventricular Ventricular Assist Devices (BIVAD), and Right Ventricular Assist Devices (RVAD)], Artificial Heart, and Intra-Aortic Balloon Pump), Type (Transcutaneous and Implantable), Therapy (Bridge-To-Transplant (BTT) Therapy, Destination Therapy, and Bridge-To-Candidacy (BTC Therapy), End-User (Hospitals, Cardiac Centers, and Ambulatory Surgical Centers), and Geography is expected to grow at a steady CAGR forecast till 2030 owing to growth in new therapies and increasing prevalence of coronary diseases.
The global cardiac assist devices market was valued at USD 2.89 billion in 2023, growing at a CAGR of 13.70% during the forecast period from 2024 to 2030, to reach USD 6.23 billion by 2030. The demand for cardiac assistance devices is motivated by a rise in the prevalence of coronary diseases, growth in new therapies, the affordability of medical devices, increasing penetration and acceptance of cardiac assistance devices in emerging countries, and innovation and advancement of medical devices.
Cardiac Assist Devices Market Dynamics:
Heart transplantation is widely regarded as the greatest therapeutic option for individuals with end-stage heart failure across the world. Only a limited percentage of patients get transplants due to the scarcity of organs available for transplantation. According to the most recent statistics, the number of patients waiting for a heart transplant has more than doubled in only five years. However, the scarcity of donors, long waiting times, and an increasing number of unstable patients have favored the development of cardiac assist.
Cardiac Assist Devices (CAD) are a type of mechanical pump that operate together with the heart to increase the effectiveness of pumping and maintain optimal blood flow across the body. To treat end-stage heart failure, cardiac aid systems are used that are determined by the individual's needs. As a result of the scarcity of cardiac donors, temporary cardiac assist devices are utilized to provide long-term assistance for individuals.
According to a report from the American Heart Association, 2020, the prevalence of heart failure continues to increase over time, with the aging of the population. It is predicted that the rising number of elderly patients would transform healthcare delivery and create a larger demand for cardiac assist devices. As per the recent survey, Global Population Aging 2020 Report (United Nations, 2020), the aging population tends to grow at an alarming pace. In 2020, there were around 727 million individuals in the world aged 65 years or older. By 2050, the figure for such patients is expected to double and reach 1.5 billion by 2050. Since the aging population is more prone to cardiovascular disorders, therefore it will give rise to more demand for cardiac assist devices, which will boost the cardiac assist devices market.
Moreover, companies are increasing their manufacturing of essential medical device products. For instance, in August 2022, the United States Food and Drug Administration (FDA) granted breakthrough device designation to Abiomed's Impella ECP expandable percutaneous heart pump. The designation means the FDA will prioritize Impella ECP's regulatory review processes including design iterations, clinical study protocols, and pre-market approval (PMA) application.
Therefore, such initiatives are expected to help the market and the patients in their treatment which will drive the cardiac assist devices market growth also.
However, high treatment costs and limitations regarding the safety of implantable devices may prove to be certain restraints to the Cardiac Assist Devices market growth.
Cardiac Assist Devices Market Segment Analysis:
Cardiac Assist Devices Market By Product (Ventricular Assist Devices [Left Ventricular Assist Devices (LVAD), Biventricular Ventricular Assist Devices (BIVAD), and Right Ventricular Assist Devices (RVAD)], Artificial Heart, and Intra-Aortic Balloon Pump), Type (Transcutaneous and Implantable), Therapy (Bridge-To-Transplant (BTT) Therapy, Destination Therapy, and Bridge-To-Candidacy (BTC Therapy), End-User (Hospitals, Cardiac Centers, and Ambulatory Surgical Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the cardiac assist devices market product segment under the ventricular assist devices category, left ventricular assist devices are expected to hold a significant share during the forecast period. It is primarily attributed to the advantages and applications associated with LVAD coupled with increasing technological advancements, the scarcity of organ donors, and the increasing prevalence of heart failure globally.
LVAD is intended for the treatment of patients with severe heart failure by restoring normal blood flow. The implantation of LVAD in heart failure patients can be life-saving and buys more time for them till organ transplantation.
LVADs are highly reliable and come with built-in safety systems.
Post implantation of LVAD, patients witness improvement in their health and can return/resume their daily activities including driving, and others.
LVADs offer intermediate to long-term treatment solutions for severe heart failure patients. Additionally, assistance from government bodies, and favorable reimbursement scenarios, are expected to enhance the cardiac assist devices market potential in several countries.
Hence, all the above-mentioned factors are expected to drive the segment growth.
North America is expected to dominate the Overall Cardiac Assist Devices Market:
Among all the regions, North America is expected to account for the largest share of the cardiac assist devices market. The growing prevalence of cardiovascular diseases, access to better healthcare infrastructure, and growing awareness regarding cardiac diseases coupled with the presence of major cardiac assist devices market players in the region are predicted to be the major influencing factors in driving the overall growth of the cardiac assist devices market over the forecast period.
The Centers for Disease Control and Prevention (CDC) 2022, estimated that about 20.1 million adults aged 20 and older had Coronary artery disease (CAD) in the US, in 2020. Also, the same source stated that in the United States, someone has a heart attack every 40 seconds. Every year, about 805,000 people in the United States have a heart attack. Out of these, 605,000 are a first heart attack, 200,000 happen to people who have already had a heart attack and about 1 in 5 heart attacks are silent-the damage is done, but the person is not aware of it.
As per the facts provided by the CDC 2020, heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States where about 655,000 Americans die from heart disease each year.
In addition, the well-established healthcare infrastructure in the country with supportive reimbursement programs covering the costs for the implantable devices as well as the procedure further encourages people to opt for such devices.
Thereby, considering the presence of a large patient pool in the US coupled with new product launches, the market for cardiac assist devices looks promising in the United States.
Cardiac Assist Devices Market Key Players:
Some of the key market players operating in the cardiac assist devices market include Abbott Laboratories, Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc, CARMAT, CorWave SA, Medtronic PLC, Terumo Heart, Inc., NovaPump GmbH, Getinge AB, Balton Ltd., Meril Life Sciences Pvt. Ltd., Thoratec Corporation, CardiacAssist, Inc., Berlin Heart GmbH, and others.
Recent Developmental Activities in the Cardiac Assist Devices Market:
In December 2020, Abbott received FDA approval for the updated labeling for the HeartMate 3 Heart Pump to be used in pediatric patients with advanced refractory left ventricular heart failure.
In March 2020, the US-based healthcare giant, SynCardia Systems LLC, got approval from the US FDA for a 50CC temporary total artificial heart system as a bridge to heart transplant for patients who are at imminent risk for death from biventricular failure.
Key Takeaways from the Cardiac Assist Devices Market Report Study
Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the global cardiac assist devices market.
Various opportunities are available for the other competitor in the cardiac assist devices market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for cardiac assist devices market growth in the coming future?
Target Audience who can be benefited from this Cardiac Assist Devices Market Report Study
Cardiac Assist Devices providers
Research organizations and consulting companies
Cardiac Assist Devices related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders in cardiac assist devices
Various End-users want to know more about the cardiac assist devices market and the latest technological developments in the cardiac assist devices market.
Frequently Asked Questions for Cardiac Assist Devices Market:
Cardiac Assist Devices (CAD) are a type of mechanical pump that operate together with the heart to increase the effectiveness of pumping and maintain optimal blood flow across the body. To treat end-stage heart failure, cardiac aid systems are used that are determined by the individual's needs. As a result of the scarcity of cardiac donors, temporary cardiac assist devices are utilized to provide long-term assistance for individuals.
The global cardiac assist devices market was valued at USD 2.89 billion in 2023, growing at a CAGR of 13.70% during the forecast period from 2024 to 2030, to reach USD 6.23 billion by 2030.
The major drivers driving the demand for cardiac assist devices are a rise in the prevalence of coronary diseases, growth in new therapies, the affordability of medical devices, increasing penetration and acceptance of cardiac assistance devices in emerging countries, and innovation and advancement of medical devices.
Some of the key market players operating in the cardiac assist devices market include Abbott Laboratories, Teleflex Incorporated, SynCardia Systems, LLC, St. Jude Medical Inc, CARMAT, CorWave SA, Medtronic PLC, Terumo Heart, Inc., NovaPump GmbH, Getinge AB, Balton Ltd., Meril Life Sciences Pvt. Ltd., Thoratec Corporation, CardiacAssist, Inc., Berlin Heart GmbH, and others.
North America is expected to dominate the overall cardiac assist devices market during the forecast period, 2024 to 2030. This domination is due to the growing prevalence of cardiovascular diseases, access to better healthcare infrastructure, and growing awareness regarding cardiac diseases coupled with the presence of major cardiac assist devices market players in the region.